Table 1.
Study design
| Group | No. of animals | Immunization | Dose level (CCID50) | Time points Immunization | Time points for necropsy and biodistribution analysis* | Time point of return to stock | Shedding analysisa | |
|---|---|---|---|---|---|---|---|---|
| Time point | Collected samplesb | |||||||
| 1 | 3 M, 3 F | NaCl | 0 | Day 1 | Day 11 | Days 0, 4, 11 | (A) | |
| 2 | 3 M, 3 F | MV1-F4 | 1.6 × 104 | Day 1 | Day 11 | Days 0, 4, 11 | (A) | |
| 3 | 3 M, 3 F | Rouvax | 3.9 × 103 | Day 1 | Day 11 | Days 0, 4, 11 | (A) | |
| 4 | 3 M, 3 F | NaCl | 0 | Days 1, 29, 57 | Day 85 | Days 0, 4, 11, 29, 56, 60, 67, 85 | (A) | |
| 5 | 3 M, 3 F | MV1-F4 | 1.6 × 104 | Days 1, 29, 57 | Day 85 | Days 0, 4, 11, 29, 56, 60, 67, 85 | (A) | |
| 6 | 3 M, 3 F | Rouvax | 3.9 × 103 | Days 1, 29, 57 | Day 85 | Days 0, 4, 11, 29, 56, 60, 67, 85 | (A) | |
| 7 | 3 mature M | MV1-F4 | 1.6 × 104 | Days 1, 29, 57 | Day 85 | Days 0, 4, 11, 29, 56, 60, 67, 85 | (B) | |
| 8 | 3 mature M | Rouvax | 3.9 × 103 | Days 1, 29, 57 | Day 85 | Days 0, 4, 11, 29, 56, 60, 67, 85 | (B) | |
M/F male/female, CCID 50 50 % cell culture infectious dose
aPretreatment = day 0; days 4, 11 and 29 = 3, 10 and 28 days after the first dose, respectively; day 56 = 1 day prior to the third dose; days 60, 67 and 85 = 3, 10 and 28 days after the third dose, respectively
b(A) PBMC, serum, throat swabs, saliva, nasal swabs, urine and vaginal secretion; (B) PBMC, semen